Sobi to refile Gamifant following CHMP rejection
The company’s peak sales forecast of more than $500 million remains unchanged
Read More
Tag: primary haemophagocytic lymphohistiocytosis
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
